Proposed Issue of Securities — IBX
July 29, 2020
Imagion Biosystems Limited has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.
Category: Investor updates
Proposed Issue of Securities — IBXOA
July 29, 2020
Imagion Biosystems has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.
IBX Raises $5M in Oversubscribed Placement
July 29, 2020
$5M raised in an oversubscribed placement at 4.5c per share – equivalent to 30 day VWAP, and a 33.9% premium to 60 day VWAP. Strongly
Appendix 2A
July 28, 2020
The application for quotation (Appendix 2A) for listed options (IBCOA) was released to the market. Read Appendix 2A.
Trading Halt
July 27, 2020
The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement regarding a
Results of the Annual General Meeting
July 22, 2020
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Imagion Biosystems Limited advises the results its 2019 Annual General
Chairman’s Address to Shareholders at Annual General Meeting
July 22, 2020
Imagion Biosystems announces the transcript of the Chairman’s address to shareholders at the Annual General Meeting. Read the transcript.
Research Shows Imagion Nanoparticles Enable Low-field MRI
July 22, 2020
Imagion Biosystems Limited is pleased to share news of research published by collaborators from the University of Sydney demonstrating that Imagion’s iron oxide nanoparticles enable
Imagion Biosystems Announces Transition of CFO Role
July 14, 2020
Imagion Biosystems Limited announces that its Chief Financial Officer, Brian Conn, will be leaving the Company effective 1st August 2020. Brian has served as a
Imagion to Work with Boston University of Next Generation Imaging Technology
July 13, 2020
Imagion Biosystems Limited (ASX: IBX) is pleased to announce it has become a member of the Nanosystems Engineering Research Center at Boston University, where researchers